Close Menu

NEW YORK – A. Menarini Diagnostics has launched two point-of-care tests for COVID-19, including an antigen test that it believes detects not only whether a patient may be infected with SARS-CoV-2 but also provides information about how infected the individual may be.

The two immunofluorescence tests run on the company's AFIAS point-of-care platform, which has two available formats and can provide results in 12 minutes. The AFIAS 1 instrument can run one sample at a time, while the AFIAS 6 runs six samples simultaneously.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.